B cells expressing IgM B cell receptors of HIV-1 neutralizing antibodies discriminate antigen affinities by sensing binding association rates.

B cell BCR CP: Immunology HIV-1 IgM affinity antigen internalization association rate calcium mobilization envelope phospho-signaling

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 06 2022
Historique:
received: 08 03 2022
revised: 09 05 2022
accepted: 08 06 2022
entrez: 29 6 2022
pubmed: 30 6 2022
medline: 2 7 2022
Statut: ppublish

Résumé

HIV-1 envelope (Env) proteins designed to induce neutralizing antibody responses allow study of the role of affinities (equilibrium dissociation constant [K

Identifiants

pubmed: 35767950
pii: S2211-1247(22)00810-5
doi: 10.1016/j.celrep.2022.111021
pmc: PMC9837990
mid: NIHMS1819977
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antigens, Viral 0
HIV Antibodies 0
Immunoglobulin M 0
Receptors, Antigen, B-Cell 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

111021

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI145656
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests None of the authors have a conflict of interest.

Références

J Exp Med. 1998 Oct 5;188(7):1297-306
pubmed: 9763609
Immunol Rev. 2017 Jan;275(1):5-10
pubmed: 28133795
Cell Host Microbe. 2014 Sep 10;16(3):304-13
pubmed: 25211073
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
J Exp Med. 2006 Apr 17;203(4):1081-91
pubmed: 16606676
Proc Natl Acad Sci U S A. 2018 May 1;115(18):4743-4748
pubmed: 29666227
Cell. 2020 Nov 25;183(5):1298-1311.e11
pubmed: 33125897
Nat Immunol. 2002 Jun;3(6):570-5
pubmed: 12021782
Sci Transl Med. 2016 Apr 27;8(336):336ra62
pubmed: 27122615
Annu Rev Immunol. 2005;23:415-45
pubmed: 15771577
Nat Rev Immunol. 2010 Nov;10(11):767-77
pubmed: 20935671
Nat Nanotechnol. 2020 Aug;15(8):716-723
pubmed: 32601450
J Exp Med. 2006 Oct 30;203(11):2419-24
pubmed: 17030950
NPJ Vaccines. 2021 Feb 9;6(1):24
pubmed: 33563983
J Immunol. 2011 Oct 1;187(7):3785-97
pubmed: 21908739
J Exp Med. 2017 Sep 4;214(9):2573-2590
pubmed: 28847869
Mol Cell. 2003 Dec;12(6):1367-78
pubmed: 14690592
Sci Signal. 2015 Sep 15;8(394):ra93
pubmed: 26373673
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
Immunity. 2000 Jul;13(1):5-14
pubmed: 10933390
Immunity. 1998 Jun;8(6):751-9
pubmed: 9655489
Science. 2006 May 5;312(5774):738-41
pubmed: 16675699
J Exp Med. 2002 May 6;195(9):1215-21
pubmed: 11994427
FEBS Lett. 2010 Dec 15;584(24):4872-7
pubmed: 20920502
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14216-21
pubmed: 21825125
J Mol Biol. 2014 Jan 9;426(1):199-214
pubmed: 24056174
Annu Rev Immunol. 1997;15:453-79
pubmed: 9143696
Immunity. 2020 Sep 15;53(3):548-563.e8
pubmed: 32857950
J Virol. 2012 Apr;86(8):4688-92
pubmed: 22301150
Front Immunol. 2021 Aug 09;12:709240
pubmed: 34434193
Immunity. 2007 Jul;27(1):160-71
pubmed: 17658276
Immunol Rev. 2017 Jan;275(1):145-160
pubmed: 28133802
Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10679-81
pubmed: 11005851
J Virol. 2013 Feb;87(3):1554-68
pubmed: 23175357
J Immunol. 2013 Aug 1;191(3):1260-75
pubmed: 23825311
Nat Commun. 2017 Nov 23;8(1):1732
pubmed: 29170366
J Exp Med. 1998 Oct 19;188(8):1453-64
pubmed: 9782122
J Immunol. 2022 Jan 15;208(2):293-302
pubmed: 34930782
Mol Immunol. 1997 Jan;34(1):63-74
pubmed: 9182877
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1254-6
pubmed: 7877964
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
Immunol Rev. 2009 Nov;232(1):34-41
pubmed: 19909354
Adv Immunol. 2014;123:69-100
pubmed: 24840948
J Immunol. 2019 Mar 1;202(5):1417-1427
pubmed: 30683703
Nature. 2010 Sep 23;467(7314):465-9
pubmed: 20818374
EMBO J. 1994 Mar 15;13(6):1341-9
pubmed: 8137818
J Immunol. 1982 Sep;129(3):1336-42
pubmed: 6286763
J Exp Med. 2021 Aug 2;218(8):
pubmed: 34106207
Curr Opin Immunol. 2006 Jun;18(3):286-91
pubmed: 16616474
Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):181-6
pubmed: 20018688
Elife. 2018 Nov 09;7:
pubmed: 30412051
Immunity. 2018 Jan 16;48(1):133-146.e6
pubmed: 29287996
J Immunol. 2012 Nov 15;189(10):4890-9
pubmed: 23066154
J Immunol. 1991 Jan 15;146(2):715-22
pubmed: 1702814
F1000Prime Rep. 2013 Oct 01;5:40
pubmed: 24167721
J Immunol. 2005 Mar 15;174(6):3369-76
pubmed: 15749869
Nat Commun. 2019 Feb 8;10(1):654
pubmed: 30737386
Immunity. 2018 Dec 18;49(6):1162-1174.e8
pubmed: 30552024
Immunity. 2016 Mar 15;44(3):542-552
pubmed: 26948373
Cell Rep. 2017 Dec 26;21(13):3681-3690
pubmed: 29281818
J Exp Med. 2013 Apr 8;210(4):655-63
pubmed: 23530120
Proc Natl Acad Sci U S A. 1982 Feb;79(3):884-8
pubmed: 6950432
Proc Natl Acad Sci U S A. 1982 Jan;79(2):395-9
pubmed: 6952192
Immunol Rev. 2012 May;247(1):11-23
pubmed: 22500828
PLoS One. 2011;6(11):e27824
pubmed: 22140469
Nat Commun. 2016 Feb 24;7:10618
pubmed: 26907590
Nat Rev Immunol. 2002 May;2(5):354-63
pubmed: 12033741
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890

Auteurs

Md Alamgir Hossain (MA)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Kara Anasti (K)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Brian Watts (B)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Kenneth Cronin (K)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Ronald Derking (R)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Bettina Groschel (B)

Department of Immunology & Microbiology and Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.

Advaiti Pai Kane (AP)

Human Vaccine Institute, Duke University, Durham, NC, USA.

R J Edwards (RJ)

Human Vaccine Institute, Duke University, Durham, NC, USA.

David Easterhoff (D)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Jinsong Zhang (J)

Applied Biomedical Science Institute, San Diego, CA, USA.

Wes Rountree (W)

Human Vaccine Institute, Duke University, Durham, NC, USA.

Yaneth Ortiz (Y)

Department of Molecular Immunology, Faculty of Biology, University of Freiburg, Freiburg, Germany.

Kevin Saunders (K)

Human Vaccine Institute, Duke University, Durham, NC, USA.

William R Schief (WR)

Department of Immunology & Microbiology and Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA; IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.

Rogier W Sanders (RW)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, Amsterdam, the Netherlands.

Laurent Verkoczy (L)

Applied Biomedical Science Institute, San Diego, CA, USA.

Michael Reth (M)

Signaling Research Centers BIOSS and CIBSS, Freiburg, Germany; Department of Molecular Immunology, Faculty of Biology, University of Freiburg, Freiburg, Germany.

S Munir Alam (SM)

Human Vaccine Institute, Duke University, Durham, NC, USA; Department of Medicine & Pathology, Duke University, Durham, NC, USA. Electronic address: munir.alam@duke.edu.

Articles similaires

Humans Interferon Type I Ross River virus Encephalitis, Tick-Borne Antibodies, Neutralizing
Humans COVID-19 Immunoglobulin G Antibodies, Viral SARS-CoV-2
Humans Malaria, Vivax Plasmodium vivax Antibodies, Protozoan Adult

Reconciling founder variant multiplicity of HIV-1 infection with the rate of CD4

James Baxter, Ch Julián Villabona-Arenas, Robin N Thompson et al.
1.00
Humans HIV-1 HIV Infections CD4-Positive T-Lymphocytes CD4 Lymphocyte Count

Classifications MeSH